Elizabeth Phillips

The University of Manchester

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Daniel Munblit

King’s College London

UNITED KINGDOM

View details

Tim Illidge

The University of Manchester

UNITED KINGDOM

View details

Sally Barrington

King’s College London

UNITED KINGDOM

View details

Suchitra Sundaram

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Derek Chu

McMaster University

CANADA

View details

Aikaterini Anagnostou

Professor of Pediatrics & Allergy

Texas Children's Hospital

UNITED STATES

View details

Alan Ramsay

King’s College London

UNITED KINGDOM

View details

Jonathan Bernstein

Professor of Clinical Medicine

University of Cincinnati

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elizabeth Phillips

Research Interests

Explore related searches

Contact this professor

Articles (16)

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper

Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach

Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Progress and pitfalls with the use of image-guided personalised approaches in lymphoma

PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma

Sequencing therapies in Hodgkin lymphoma

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.

Burkitt Lymphoma International Prognostic Index.

TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.

Collaborators (8)

Daniel Munblit

Tim Illidge

Sally Barrington

Suchitra Sundaram

Derek Chu

Aikaterini Anagnostou

Alan Ramsay

Jonathan Bernstein

Make your next move.